Latest Headlines
-
Ultra-High Precision Optical Flats
6/25/2026
Optical Surfaces Ltd. is a leading supplier of ultra-high precision optical flats to research establishments and national standards laboratories worldwide.
-
Versant Diagnostics Expands Collaboration With Leica Biosystems As PRW Laboratories Becomes First To Deploy Aperio GT Elite Solution
6/24/2026
Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Versant Diagnostics, an independent physician services company actively engaged in next-generation digital pathology, announce an expanded collaboration to advance digital pathology adoption.
-
Legacy Receives New York State CLEP Approval For Two Laboratory-Developed Tests: Semen Analysis And DNA Fragmentation
6/24/2026
Legacy, a leading male fertility testing and sperm preservation company, today announced that the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP), administered by the Wadsworth Center, has validated and approved two of its laboratory-developed tests: semen analysis and sperm DNA fragmentation analysis.
-
ALZpath Signs Global Licensing Agreement With Abbott To Advance Blood-Based Alzheimer's Disease Testing
6/24/2026
ALZpath Inc., the leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced a licensing agreement with Abbott (NYSE: ABT), a global healthcare leader, to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into the development of an in vitro diagnostic (IVD) test for Alzheimer's disease.
-
VERAXA Biotech Expands R&D Hub In Heidelberg As Innovative BiTAC™-TCE And ADC Programs Advance Towards Clinical Development
6/24/2026
VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has moved into additional laboratory space at its existing R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement.
-
Quest Diagnostics Receives New York State Approval For Haystack MRD®, Broadening Patient Access To ctDNA Minimal Residual Disease Testing
6/24/2026
Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.
-
UF Researchers Develop Rapid Urine Diagnostic Test For Prostate Cancer
6/23/2026
Accurately diagnosing prostate cancer is a challenge. Current screening methods using blood tests sometimes show abnormal results even when a man does not have cancer, or normal results when he does.
-
Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development And AI-Enabled Research At BIO International 2026
6/22/2026
Thermo Fisher Scientific, the world leader in serving science, will showcase new capabilities, strategic investments and initiatives at BIO International 2026 that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster.
-
DNREC Opens New Delaware Environmental Laboratory In Smyrna
6/18/2026
The Department of Natural Resources and Environmental Control’s Delaware Environmental Laboratory has opened near Smyrna, providing a state-of-the-art facility to test water quality, chemical contaminants including per- and poly fluoroalkyl substances (PFAS) and conduct molecular and microbiology.
-
PHC Launches Cell-IQ CO₂ Incubators With Active Humidity Control, Creating Critical Stability For Research Samples
6/18/2026
PHC Corporation of North America (PHCNA), provider of PHCbi cell culture and sample preservation solutions across North America and Latin America, has introduced a new series of laboratory incubators featuring active hybrid humidification technology and enhanced contamination control.